Company profile
Ticker
HURA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Berry Only Inc., DelMar Pharmaceuticals, Inc., Kintara Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Del Mar Pharmaceuticals (BC) Ltd. • 0959454 B.C. Ltd. • 0959456 B.C. Ltd. • Adgero Biopharmaceuticals Holdings, Inc. • Adgero Biopharmaceuticals, Inc. • Kayak Mergeco, Inc. ...
IRS number
990360497
HURA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
14 Feb 25
S-4
Registration of securities issued in business combination transactions
7 Feb 25
8-K
Changes in Registrant's Certifying Accountant
3 Jan 25
S-8
Registration of securities for employees
23 Dec 24
425
Business combination disclosure
12 Dec 24
8-K
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire
12 Dec 24
8-K
Regulation FD Disclosure
25 Nov 24
8-K
Departure of Directors or Certain Officers
15 Nov 24
8-K/A
Completion of Acquisition or Disposition of Assets
14 Nov 24
10-Q
2025 Q1
Quarterly report
14 Nov 24
Latest ownership filings
4
Robert E. Hoffman
6 Jan 25
4
JAMES S J MANUSO
6 Jan 25
4
Alan List
6 Jan 25
4
George K Ng
6 Jan 25
4
James A. Bianco
14 Nov 24
4
Dan Dearborn
14 Nov 24
SC 13G
Theofilos Charles Steve
25 Oct 24
SC 13G
Patel Samir Rashmikant
25 Oct 24
SC 13G
KP Biotech Group LLC
25 Oct 24
SC 13G
CA Patel F&F Investments, LLC
25 Oct 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 24 | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 3.02 mm | 3.02 mm | 3.02 mm | 3.02 mm | 3.02 mm | 3.02 mm |
Cash burn (monthly) | 629.67 k | (no burn) | 720.00 k | 626.00 k | 629.67 k | 645.67 k |
Cash used (since last report) | 2.99 mm | n/a | 3.42 mm | 2.97 mm | 2.99 mm | 3.06 mm |
Cash remaining | 32.45 k | n/a | -396.15 k | 49.85 k | 32.45 k | -43.46 k |
Runway (months of cash) | 0.1 | n/a | -0.6 | 0.1 | 0.1 | -0.1 |
Institutional ownership, Q3 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 25 | George K Ng | Options Common Stock | Grant | Acquire A | No | No | 4.11 | 51,275 | 210.74 k | 51,275 |
2 Jan 25 | James S J Manuso | Options Common Stock | Grant | Acquire A | No | No | 4.11 | 59,590 | 244.91 k | 59,590 |
2 Jan 25 | Hoffman Robert | Options Common Stock | Grant | Acquire A | No | No | 4.11 | 51,275 | 210.74 k | 51,275 |
2 Jan 25 | Alan List | Options Common Stock | Grant | Acquire A | No | No | 4.11 | 51,275 | 210.74 k | 51,275 |
12 Nov 24 | James A Bianco | Options Common Stock | Grant | Acquire A | No | No | 4.94 | 1,065,990 | 5.27 mm | 1,065,990 |
News
Rodman & Renshaw Initiates Coverage On TuHURA Biosciences with Buy Rating, Announces Price Target of $11
2mo ago
TuHURA To Acquire Kineta, Adding KVA12123 Checkpoint Inhibitor To Late-Stage Pipeline; Targeting Phase 2a/b Trial For Mutated NPM1 AML In 2025; Cross Product Synergies Enhance TuHURA's Cancer Immunotherapy Focus; Proposed Transaction Closing Expected Q1 2025
2mo ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
2mo ago
TuHURA Biosciences Outlines Development Pathway For Single Phase 3 Accelerated Approval Registration Trial
2mo ago
Press releases
TuHURA Biosciences, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
1d ago
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand
1d ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders
2mo ago
Kuehn Law Encourages VOXX, CARA, VTS, and HURA Investors to Contact Law Firm
2mo ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
2mo ago